Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Clinical trial NCT04738487 · COMPLETED
Trial details
- NCT number
- NCT04738487
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-07
- Primary completion
- 2024-09-05
- Enrollment
- 1264
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.